JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on the Potential of Selected Phytopharmaceuticals for Central Nervous System Disorders

Sayyad Arshiya[1], Sai Krishna Nallajerla[*1], Srinivasu M[1], Anusha Kusuma[1], SS Prasanna Kumar Ponnaganti[1], Anil Kumar Vadaga[2]

[1]*Department of Pharmacy, A.K.R.G College of Pharmacy, Nallajerla, Andhra Pradesh, India*
[2] *Department of Pharmaceutics, School of Pharmacy, Godavari Global University, Rajahmundry, Andhra Pradesh, India*

Publication history: Received on 2nd April 2026; Revised on 7th May 2026; Accepted on 9th May 2026

Article DOI: 10.69613/n8yket13

Abstract: The global burden of central nervous system disorders, including neurodegenerative, neuropsychiatric, and neuroinflammatory conditions, poses a critical public health challenge. Conventional synthetic therapeutics often present significant limitations, such as adverse side-effect profiles, narrow therapeutic indexes, and a lack of disease-modifying efficacy. Consequently, natural products derived from historical ethnomedical systems serve as an invaluable reservoir for drug discovery. Among these, *Withania somnifera*, *Bacopa monnieri*, *Valeriana officinalis*, *Cinnamomum zeylanicum*, and *Rhodiola rosea* have demonstrated profound neuroprotective, nootropic, and adaptogenic properties. These agents act by several molecular cascades rather than single-target interactions. The main neuroprotective pathways include the regulation of the hypothalamic-pituitary-adrenal axis, suppression of pro-inflammatory cytokines, enhancement of antioxidant enzyme expression, inhibition of acetylcholinesterase, and modulation of fundamental neurotransmitter systems such as GABAergic, serotonergic, and dopaminergic pathways. These phytopharmaceuticals demonstrate the capacity to prevent toxic protein aggregation, promote synaptic plasticity, and stimulate dendritic arborization. Preclinical investigations validate their systemic efficacy in animal models of Alzheimer's disease, Parkinson's disease, stroke, and chronic stress-induced cognitive decline. Human clinical trials increasingly substantiate their safety, tolerability, and therapeutic merit, although rare safety concerns such as transient cholestatic hepatotoxicity require vigilant monitoring. Combining these validated ethnopharmacological agents into contemporary neurology represents a promising strategy for developing novel, multi-target neurotherapeutics. Scientific validation through reverse pharmacology methods bridges the gap between empirical use and modern evidence-based clinical neurology, optimizing treatment outcomes for various neuropathological conditions.

Keywords: Ethnopharmacology; Neurotherapeutics; Phytochemistry; Synaptic plasticity, Neurodegeneration.

1. Introduction

Globally, neurological and mental health conditions are regarded as a major impediment to human health and economic productivity. This burden is particularly pronounced in low-to-middle-income countries where access to specialized neurological care is restricted, and cultural frameworks steer patients toward traditional therapeutic modalities [1]. The global herbal medicine sector relies on the empirical, historical utilization of botanical remedies documented within specialized ethnomedical systems. India possesses a rich historical heritage in this domain, primarily represented by Ayurveda and Siddha medicine, which have collectively preserved thousands of formulations targeting cognitive decline, emotional instability, and convulsive states [2]. The World Health Organization has explicitly emphasized the systemic value of exploring natural products to address unmet clinical needs, particularly in neurology where many modern synthetic pharmaceuticals fail to halt disease progression [3].

Despite widespread empirical use, a substantial gap exists regarding the rigorous molecular characterization and pharmacokinetic validation of these traditional treatments. Over one billion individuals are estimated to suffer from central or peripheral nervous system disorders globally [4]. These conditions of highly complex diseases such as schizophrenia, epilepsy, Parkinson's disease, stroke, and Alzheimer's disease [5]. The modern pharmacological pipeline has struggled to produce effective treatments for these conditions, largely because of the highly restrictive blood-brain barrier and the multifactorial pathogenesis of neurodegeneration, which limits the efficacy of single-target synthetic molecules [6].

Consequently, there is a major clinical incentive to explore multi-component, multi-target botanical extracts. Ayurveda, for instance, documents approximately 2000 plant species possessing distinct therapeutic values, while the traditional Chinese pharmacopoeia

* Corresponding author: Sai Krishna Nallajerla

Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0.

catalogues over 5700 medicinal materials [7]. The paradigm of drug discovery in these traditional systems increasingly utilizes reverse pharmacology [8]. Unlike the conventional laboratory-to-clinic pipeline, reverse pharmacology initiates the discovery process through documented clinical efficacy and historical safety data in human populations, subsequently moving backward to validate these findings via standardized preclinical models, molecular docking, and mechanistic evaluation *in vitro* [9]. This methodology significantly reduces the translational failures commonly observed in prospective drug development [10].

Among the diverse botanical materials designated for neurological health, a specialized subset of adaptogenic, nootropic, and sedative plants has emerged as highly promising candidates. These include *Withania somnifera*, *Bacopa monnieri*, *Valeriana officinalis*, *Cinnamomum zeylanicum*, and *Rhodiola rosea* [11]. These plants contain complex matrices of secondary metabolites that cross the blood-brain barrier to modulate neurotransmitter receptors, alleviate oxidative stress, reduce neuroinflammation, and prevent aberrant protein folding. A thorough analysis of their chemical composition, specific mechanism of action, and translational clinical evidence is required to fully position them as viable modern neurotherapeutics.

2. History of Traditional Remedies

The therapeutic utilization of crude botanical preparations and standardized extracts forms the foundation of herbalism, an ancient clinical science that preceded modern chemistry by millennia [12]. Across global cultures, the historical *materia medica* was predominantly vegetative, reflecting a deep co-evolutionary relationship between human populations and regional flora. Herbal medicine, formally referred to as phytotherapy or botanical medicine, relies on the synergistic interactions of multiple chemical compounds within a single plant part, rather than isolating a solitary chemical entity [13].

Within the Indian subcontinent, traditional herbal systems have maintained a continuous, documented clinical practice for over five thousand years. The philosophical and practical basis of Ayurvedic medicine is rooted in the concept that virtually all natural substances possess pharmacological activity when administered under appropriate clinical paradigms [14]. Ayurvedic physicians meticulously documented the therapeutic properties, adverse effects, and processing methods of hundreds of plants. Today, a significant percentage of the Indian population continues to rely on these traditional systems for primary healthcare, highlighting the enduring sociological and clinical relevance of phytotherapy [15]. This historical foundation provides a vast library of ethnobotanical leads that have survived centuries of clinical observation, offering a highly enriched starting point for modern neurodegenerative and neuropsychiatric drug discovery.

3. Selected Ethnopharmacological Sources

3.1. *Withania somnifera*

Withania somnifera, popularly referred to as Ashwagandha or Indian Ginseng, is a premier botanical lead within the traditional Indian pharmacopoeia, historically utilized as a *Rasayana* (rejuvenating agent) to promote longevity, arrest age-related cognitive decline, and enhance physical and mental resilience [16]. Introduced into formal documented use around 6000 BC, this species has been widely integrated into formulas designed to manage anxiety, sleep disturbances, cognitive deficits, and neurodegenerative states [17].

Figure 1. Whole Plant of *Withania Somnifera*

The species name *somnifera* reflects its potent sleep-inducing and anxiety-reducing properties, while the vernacular term *ashwagandha* relates to the characteristic odor of the fresh root, which translates metaphorically to the strength and vitality of a horse [18]. Modern pharmacological investigations have focused on the root and leaf extracts of this plant, identifying key secondary metabolites capable of modulating the mammalian central nervous system [19]. It has shown therapeutic potential across a spectrum of

neuropathological conditions, including Alzheimer's disease, Parkinson's disease, cerebral ischemia, tardive dyskinesia, and clinical anxiety [20].

3.1.1. Phytochemical Profile and Structural Chemistry

The therapeutic efficacy of *Withania somnifera* is attributed to a complex mixture of steroidal lactones and alkaloids. The primary bioactive markers are the withanolides, which are naturally occurring C28-steroidal lactones structurally based on an intact ergostane skeleton [21]. Within this class, oxidation at the C22 and C26 positions results in the cyclization and formation of a characteristic six-membered lactone ring. The fundamental structure is defined as 22-hydroxy-ergostan-26-oic acid-26,22-lactone [22].

To date, researchers have isolated more than thirty-five distinct withanolides, twelve alkaloids, and several sitoinodosides from the root extracts. Withaferin A was the first withanolide isolated and characterized, showing potent anti-inflammatory and anti-proliferative activities. For central nervous system indications, the key active compounds include withanolide A, withanoside IV, withanoside VI, and withanone. The alkaloid fraction contains structurally diverse compounds, including withanine, pseudowithanine, somniferine, somniferinine, tropine, pseudotropine, choline, cuscohygrine, isopelletierine, anaferine, and anahydrine [23]. Additionally, the roots are rich in sitoindosides VII, VIII, IX, and X, which are withanolides containing an acylglycoside moiety at the C27 position [24]. These glycosidic conjugates exhibit high water solubility and superior bioavailability compared to the aglycone withanolides, allowing them to exert systemic adaptogenic actions.

Table 1. Botanical, Traditional, and Phytochemical Profiles of Selected Neuroprotective Leads

Botanical Name	Plant Family	Common / Traditional Names	Primary Plant Parts Used	Major Bioactive Compound Classes	Phytochemical Constituents
Withania somnifera (L.) Dunal	Solanaceae	Ashwagandha, Indian Ginseng	Roots, leaves	Steroidal lactones (withanolides), alkaloids, sitoindosides	Withaferin A ($C_{28}H_{38}O_6$), Withanolide A ($C_{28}H_{38}O_6$), Withanoside IV ($C_{49}H_{74}O_{23}$), Sominone ($C_{28}H_{40}O_6$)
Bacopa monnieri (L.) Wettst.	Scrophulariaceae	Brahmi, Water Hyssop	Whole herb, aerial parts	Triterpenoid saponins (bacosides), alkaloids, sterols	Bacoside A3 ($C_{47}H_{76}O_{18}$), Bacopaside I ($C_{41}H_{68}O_{13}S$), Bacopasaponin C ($C_{47}H_{76}O_{18}$), Brahmine ($C_{13}H_{21}NO_3$)
Valeriana officinalis L.	Caprifoliaceae	Valerian, All-Heal	Roots, rhizomes	Volatile sesquiterpenes, iridoids (valepotriates), flavonoids	Valerenic acid ($C_{15}H_{22}O_2$), Valtrate ($C_{22}H_{32}O_8$), Linarin ($C_{28}H_{32}O_{14}$), Acetoxyvalerenic acid ($C_{17}H_{24}O_4$)
Cinnamomum zeylanicum Blume	Lauraceae	Ceylon Cinnamon	Bark, leaves	Phenylpropanoids, monoterpenes, condensed tannins	Trans-cinnamaldehyde (C_9H_8O), Cinnamic acid ($C_9H_8O_2$), Eugenol ($C_{10}H_{12}O_2$), Cinnamyl acetate ($C_{11}H_{12}O_2$)
Rhodiola rosea L.	Crassulaceae	Golden Root, Arctic Root	Rhizomes, roots	Phenylpropanoids (rosavins), phenylethanols, flavonoids	Salidroside ($C_{14}H_{20}O_7$), Rosavin ($C_{20}H_{28}O_{10}$), p-Tyrosol ($C_8H_{10}O_2$), Rosarin ($C_{20}H_{28}O_{10}$)

3.1.2. Molecular and Cellular Mechanisms of Action

The neuropharmacological actions of *Withania somnifera* operate through several distinct cellular pathways:

- Hypothalamic-Pituitary-Adrenal (HPA) Axis Regulation: Under chronic stress, the HPA axis becomes hyperactive, resulting in sustained elevations of systemic cortisol. This hypercortisolemia induces hippocampal atrophy, dendritic retraction, and cognitive impairment. *Withania somnifera* acts as a systemic adaptogen by directly modulating HPA axis sensitivity. The glucowithanolide constituents mimic certain endogenous corticosteroids, providing negative feedback inhibition to the hypothalamus and pituitary gland. This results in a significant reduction in circulating cortisol levels and a concomitant increase in dehydroepiandrosterone (DHEA), an endogenous neurosteroid that promotes synaptic plasticity and elevates mood.

- Synaptic Reconstruction and Axonal Regeneration: In neurodegenerative states, the loss of synaptic connectivity precedes neuronal death. Preclinical studies indicate that withanolide A and withanoside IV can induce significant neurite outgrowth, axonal regeneration, and synaptic reconstruction. In damaged or degenerating cortical neurons, the administration of withanolide A stimulates the outgrowth of both axons and dendrites. Withanoside IV is metabolized *in vivo* to sominone, an active aglycone that exhibits enhanced neuroregenerative capacity, facilitating the recovery of spatial memory and motor coordination by rebuilding functional synaptic connections.
- Attenuation of Amyloid-Beta (Aβ) Neurotoxicity: The accumulation of amyloid-beta peptides (Aβ1-40 and Aβ1-42) into oligomers and senile plaques is a primary pathological driver of Alzheimer's disease. *Withania somnifera* protects neurons from this toxic insult through the actions of withanamides A and C. These specific compounds bind directly to the hydrophobic core of the Aβ peptide, preventing the self-assembly of monomers into toxic oligomers and fibrils. Additionally, the extract upregulates the low-density lipoprotein receptor-related protein (LRP) in the brain vasculature, which accelerates the clearance of Aβ across the blood-brain barrier into the systemic circulation, thereby reducing the cerebral amyloid burden.

3.1.3. Preclinical and Clinical Evidence

The neuroprotective properties of *Withania somnifera* are strongly supported by rigorous preclinical studies. *In vitro* evaluations using pheochromocytoma (PC12) cell lines demonstrate that pretreatment with standardized aqueous-alcoholic root extracts significantly protects cells from hydrogen peroxide (H_2O_2) and Aβ1-42-induced cytotoxicity in a concentration-dependent manner [27]. This cytoprotection is mediated by a reduction in intracellular reactive oxygen species (ROS) generation, preservation of mitochondrial membrane potential, and down-regulation of pro-apoptotic markers such as cleaved caspase-3 and Bax, while up-regulating the anti-apoptotic protein Bcl-2. Experimental research on seed-derived fatty acids extracted via supercritical fluid extraction shows a robust suppression of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), highlighting the systemic anti-inflammatory actions of the plant's diverse chemical components [28]. Structural and immunological assessments of specialized polysaccharides, such as AP-1, isolated from the roots, reveal strong immunostimulatory and cytoprotective properties that help maintain cellular homeostasis under pathological stress [29].

Despite its therapeutic promise, clinical integration requires careful attention to the plant's safety profile. Detailed toxicological evaluations in animal models show that standardized extracts are highly tolerated, with no significant acute or sub-acute toxicity observed [30]. However, clinical case reports have identified rare adverse events that require vigilance. Standardized supplements have been linked to transient drug-induced liver injury, specifically cholestatic hepatitis, which manifests as elevated serum bilirubin and alkaline phosphatase. This condition typically resolves fully upon discontinuation of the supplement [25]. Additionally, *Withania somnifera* can stimulate the thyroid gland, leading to elevated levels of triiodothyronine (T3) and thyroxine (T4). Consequently, patients with pre-existing autoimmune thyroid disease or subclinical hyperthyroidism must be monitored closely, as cases of clinically overt thyrotoxicosis presenting with supraventricular tachycardia have been documented [26].

3.2. *Bacopa monnieri*

Bacopa monnieri, a small perennial creeping herb belonging to the Scrophulariaceae family, has been recognized for over three millennia in Ayurvedic medicine as a premier *Medhya Rasayana* (brain rejuvenator) [31]. Known historically as Brahmi, this botanical lead is traditionally administered to elevate memory acquisition, enhance cognitive focus, alleviate clinical anxiety, and manage convulsive disorders such as epilepsy [32]. As an established nootropic, the pharmacological actions of this plant extend beyond simple symptomatic relief, promoting synaptic plasticity, repairing damaged structural networks, and restoring balanced neurotransmission within highly vulnerable brain regions [33,34].

Figure 2. Flowers and Leaves of *Bacopa mannieri*

3.2.1. Phytochemical and Structural Chemistry

The neurological efficacy of *Bacopa monnieri* is driven by its diverse array of specialized secondary metabolites, primarily consisting of steroidal and triterpenoid saponins [31]. The principal bioactive agents are the dammarane-type triterpenoid saponins designated as bacosides [35]. Bacoside A is the major active mixture, which chromatographic analysis reveals to be a complex of four distinct saponin entities: bacoside A3, bacopaside II, bacopasaponin C, and the isomer of bacopaside I [36]. Structurally, these saponins consist of a hydrophobic dammarane triterpenoid skeleton conjugated with various hydrophilic sugar chains, such as glucose, arabinose, or sulfated glycosyl residues, at the C3 or C20 positions.

Beyond the core bacoside A complex, the plant contains bacoside B, saponins A, B, and C, and specific monomeric triterpenoid glycosides such as pseudojujubogenin and jujubogenin glycosides [31,37]. The alkaloid fraction is represented by brahmine, which works alongside sterols and triterpenes including β-sitosterol, stigmasterol, stigmastanol, betulinic acid, and D-mannitol [32,35]. Essential amino acids such as α-alanine, aspartic acid, glutamic acid, and serine are also present, facilitating metabolic homeostasis within the central nervous system. The precise ratio of these secondary metabolites dictates the overall cognitive-enhancing and neuroprotective capability of the crude extract.

3.2.2. Molecular and Cellular Mechanisms of Action

The primary molecular mechanisms of *Bacopa monnieri* involve a cascade of intracellular and synaptic pathways:

- Neurotransmitter Modulation and Acetylcholinesterase Inhibition: *Bacopa monnieri* directly modulates synaptic transmission by altering the synthesis and degradation of key neurotransmitters [36]. The active bacosides serve as moderate inhibitors of the enzyme acetylcholinesterase (AChE), which is responsible for the hydrolysis of acetylcholine (ACh) within the synaptic cleft. By prolonging the biological half-life of ACh, the extract enhances cholinergic transmission in the hippocampus and cerebral cortex, thereby improving spatial learning and memory retrieval. Concurrently, the bioactive compounds modulate the serotonergic system by up-regulating tryptophan hydroxylase and the serotonin transporter (SERT), which helps stabilize mood, and also balance dopaminergic pathways to optimize attention span and executive functioning.
- BDNF-CREB Signaling Pathways and Dendritic Arborization: The nootropic properties of *Bacopa monnieri* are linked to its ability to stimulate neuroplasticity [35]. At the cellular level, bacoside A up-regulates the expression of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, tropomyosin receptor kinase B (TrkB), in the hippocampus. This activation triggers downstream phosphorylation cascades, including the cyclic adenosine monophosphate (cAMP) response element-binding (CREB) protein pathway and the mitogen-activated protein kinase (MAPK) pathway. This molecular signaling cascade promotes the survival of newborn neurons, stimulates dendritic arborization, and facilitates the development of new synaptic connections, resulting in enhanced long-term potentiation.
- Mitigation of Neuroinflammation and Microglial Activation: Neurodegenerative diseases are characterized by chronic, low-grade neuroinflammation driven by overactive microglia. *Bacopa monnieri* exerts potent anti-inflammatory effects by inhibiting the nuclear factor kappa B (NF-ϰB) signaling cascade within activated microglial cells. This inhibition decreases the transcription and release of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and inducible nitric oxide synthase (iNOS). By suppressing this localized inflammatory response, the extract prevents bystander neuronal apoptosis and preserves blood-brain barrier integrity.

3.2.3. Preclinical and Clinical Evidence

Preclinical investigations provide robust *in vivo* evidence validating the systemic efficacy of *Bacopa monnieri*. In rodent models of age-associated memory impairment and cognitive decline, oral supplementation with standardized extracts over four to twelve weeks significantly improves performance in spatial navigation tests, such as the Morris water maze, and passive avoidance tasks [43]. In chemically induced models of Parkinson's disease using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), preclinical administration of *Bacopa monnieri* extract demonstrated significant neuroprotective and neurorescue properties. The treatment rescued dopaminergic neurons in the substantia nigra, suppressed microglial activation, lowered lipid peroxidation, and recovered motor coordination deficits [44]. Additionally, rodent studies indicate that chronic administration increases the expression of endogenous antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), in the frontal cortex and striatum, protecting the brain against age-induced oxidative damage [45].

These preclinical findings translate consistently into human clinical trials. Randomized, double-blind, placebo-controlled trials in both healthy volunteers and elderly populations show that standardized *Bacopa monnieri* extracts significantly improve verbal learning, rate of information processing, delayed word recall, and attention span, while concurrently decreasing state anxiety [34,38]. Synergistic combinations with other neuroprotective agents, such as Gotu Kola (*Centella asiatica*), have also shown promise in maintaining cognitive reserves in patients experiencing early-stage cognitive decline [39]. Clinical evaluations confirm that the herb

is well tolerated in therapeutic doses, with a low incidence of adverse effects [40]. *In vitro* assessments on human neuroblastoma cell lines (SH-SY5Y) have further confirmed these clinical observations, demonstrating that the extract alters gene expression profiles related to cell survival, stress resistance, and synaptic transmission, thereby establishing a solid translational pathway from laboratory bench to bedside [41,42].

3.3. *Valeriana officinalis*

Valeriana officinalis, commonly referred to as Valerian, has a long history in European and Asian traditional medicine, with documented clinical applications dating back to ancient Greece and Rome, where practitioners such as Galen and Hippocrates prescribed it for physical and psychological ailments [46]. A perennial herb belonging to the Caprifoliaceae family, its roots and rhizomes produce a distinct essential oil widely used as an anxiolytic, sedative, and sleep-promoting agent [47,48]. Standardized preparations are frequently recommended as natural alternatives to synthetic sedative-hypnotics, such as benzodiazepines, which often present challenges related to dependency, cognitive impairment, and morning somnolence [49,50].

Figure 3. Flowers and Leaves of *Valeriana officinalis*

3.3.1. Phytochemical and Structural Chemistry

The therapeutic action of *Valeriana officinalis* is driven by a complex synergy among several chemical classes within its subterranean structures. The plant contains volatile oils, iridoids (valepotriates), flavonoids, and free amino acids [51,52]. The volatile oil fraction is rich in monoterpenes and sesquiterpenes, with key chemical markers being valerenic acid, acetoxyvalerenic acid, hydroxyvalerenic acid, valerenal, and valeranone [52]. Valerenic acid ($C_{15}H_{22}O_2$) is a specific sesquiterpene biomarker utilized to standardize commercial extracts.

The iridoid fraction is composed of valepotriates, which are lipophilic triesters of an iridoid nucleus containing an epoxide ring. The primary compounds in this class are valtrate, isovaltrate, and acevaltrate [53]. Although these molecules are chemically unstable and decompose during processing or exposure to gastric acid into baldrinals and homobaldrinals, they contribute to the central effects of the plant. The flavonoid content is represented by apigenin, 6-methylapigenin, and linarin (acacetin-7-O-rutinoside), which exhibit distinct central nervous system activity [51]. Additionally, the roots contain significant levels of free amino acids, specifically gamma-aminobutyric acid (GABA), glutamine, and tyrosine, which contribute to the herb's neuroactive properties.

3.3.2. Molecular and Cellular Mechanisms of Action

The central nervous system effects of *Valeriana officinalis* are mediated primarily by modulating the main inhibitory neurotransmitter pathway:

- Allosteric Modulation of the GABAA Receptor Complex: The primary active constituent, valerenic acid, acts as a potent, subtype-specific, positive allosteric modulator of the gamma-aminobutyric acid type A (GABAA) receptor [53]. Valerenic acid binds to a specific hydrophobic cavity on the channel's β2 or β3 subunits. This binding stabilizes the open state of the

ligand-gated chloride channel, increasing chloride ion (Cl^-) influx into the postsynaptic neuron. The resulting hyperpolarization shifts the membrane potential further from the threshold needed to fire an action potential, reducing neuronal excitability and manifesting clinically as sedation and anxiolysis.

- Inhibition of GABA Transaminase and Reuptake: Beyond direct receptor interaction, *Valeriana officinalis* extracts alter endogenous GABA levels [54]. The active constituents inhibit the enzyme gamma-aminobutyric acid transaminase (GABA-T), which is responsible for the catabolic breakdown of GABA into succinic semialdehyde. The extract inhibits the sodium-dependent GABA transporter (GAT) on astrocytes and presynaptic terminals, reducing the reuptake of released GABA from the synaptic cleft. This dual mechanism increases the local concentration and duration of action of endogenous GABA within the brain, amplifying inhibitory neurotransmission.
- Serotonergic and Adenosinergic Modulation: The volatile components of *Valeriana officinalis* also interact with non-GABAergic pathways [51,52]. Studies show that certain constituents bind to the 5-HT1A and 5-HT2A serotonin receptors, as well as the A1 adenosine receptor, contributing to the herb's antidepressant-like and sleep-inducing qualities.

3.3.3. Preclinical and Clinical Evidence

The molecular actions of *Valeriana officinalis* are well supported by *in vitro* and *in vivo* studies. Binding assays utilizing isolated rat brain synaptic membranes confirm that valerenic acid and crude valerian extracts displace radiolabeled GABA ligands from receptor sites and inhibit GABA-T activity [54]. In rodent behavioral models, acute oral administration of standardized valerian root extract or isolated valerenic acid produces significant anxiolytic and sedative effects in the elevated plus-maze and open-field tests, comparable to low doses of diazepam, without inducing severe muscle relaxation or locomotor impairment [55,56]. In a model of asthma-induced neuroimmune stress in ovalbumin-sensitized rats, treatment with a hydro-alcoholic extract of valerian significantly reduced depression-like behavior in the forced swim test. This antidepressant effect was associated with a decrease in systemic and central inflammatory cytokines, suggesting that valerian helps protect the central nervous system during inflammatory stress [57].

Clinical studies in humans support the use of *Valeriana officinalis* for managing insomnia, sleep fragmentation, and mild nervous tension [47]. Meta-analyses of randomized clinical trials indicate that standardized valerian preparations improve subjective sleep quality, reduce sleep latency, and increase slow-wave (deep) sleep without causing the next-day hangover effect typical of conventional benzodiazepines [48,49]. Clinical safety assessments show that valerian root possesses a favorable therapeutic index and is well tolerated at standard doses over moderate periods [58]. The absence of significant dependency or withdrawal symptoms further supports its use as a viable therapeutic option for managing mild sleep disturbances and anxiety.

3.4. *Cinnamomum zeylanicum*

Cinnamomum zeylanicum, commonly referred to as Ceylon cinnamon, is a highly valued evergreen tree belonging to the Lauraceae family [59]. While historically prized for its culinary and preservative applications, its bark and leaves contain a dense repository of highly specialized secondary metabolites that have been utilized in traditional medicine systems to address various inflammatory, metabolic, and neurological ailments [60]. Systematic evaluations of this plant highlight its multi-target efficacy in mitigating neuropathological pathways associated with progressive neurodegenerative conditions. The therapeutic potential of *Cinnamomum zeylanicum* is particularly relevant to central nervous system disorders characterized by elevated levels of pro-inflammatory biomarkers, chronic oxidative stress, and aberrant protein aggregation [61,62].

Figure 4. Leaves and Flowering Tops of *Cinnamomum zeylanicum*

3.4.1. Phytochemical and Structural Chemistry

The volatile oil and organic extracts obtained from the bark and leaves of *Cinnamomum zeylanicum* contain a rich array of phenylpropanoids, monoterpenes, and polyphenolic compounds [61]. The primary bioactive marker is trans-cinnamaldehyde (C_9H_8O), an unsaturated aldehyde that accounts for up to eighty percent of the bark's essential oil content. Additional major constituents include cinnamic acid ($C_9H_8O_2$), cinnamyl acetate ($C_{11}H_{12}O_2$), eugenol ($C_{10}H_{12}O_2$), and camphor ($C_{10}H_{16}O$).

The leaf oil exhibits a distinct chemical profile, dominated by eugenol rather than cinnamaldehyde, which introduces a different spectrum of anti-inflammatory and analgesic activities. Minor terpenoid constituents, including borneol ($C_{10}H_{18}O$), L-borneol, terpineol ($C_{10}H_{18}O$), and E-nerolidol ($C_{15}H_{26}O$), work synergistically to enhance the overall lipophilicity and cellular uptake of the extract [61]. *Cinnamomum zeylanicum* contains highly specialized B-type procyanidin oligomers. These condensed tannins consist of catechin and epicatechin subunits linked by single C4 → C8 or C4 → C6 carbon-carbon bonds. These oligomeric structures possess a high density of phenolic hydroxyl groups, which provide exceptional free radical scavenging capacity and directly interfere with the structural assembly of toxic protein aggregates within the cerebral parenchyma [64].

3.4.2. Molecular and Cellular Mechanisms of Action

The neuroprotective mechanisms of *Cinnamomum zeylanicum* operate through multiple cellular pathways:

- *In Vivo* Metabolic Conversion to Sodium Benzoate (NaB): Upon ingestion, cinnamaldehyde is rapidly metabolized in the liver via hepatic oxidation pathways into cinnamic acid, which is subsequently converted into sodium benzoate (NaB). Sodium benzoate is a highly soluble, clinically approved compound that readily crosses the blood-brain barrier. Within the central nervous system, NaB serves as a major pharmacological agent. It upregulates the cyclic adenosine monophosphate (cAMP) response element-binding (CREB) protein pathway within hippocampal neurons. This activation increases the transcription of essential neurotrophic factors, specifically brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), which are crucial for maintaining synaptic plasticity, dendritic spine density, and long-term potentiation.
- Suppression of Microglial Activation and Neuroinflammation: Chronic neuroinflammation driven by overactive microglia is a key driver of progressive neuronal loss. Trans-cinnamaldehyde directly inhibits the activation of microglia by blocking the nuclear translocation of the transcription factor nuclear factor kappa B (NF-ϰB). This molecular blockade suppresses the transcription of inflammatory genes, leading to a significant reduction in the release of nitric oxide (NO), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-alpha (TNF-α) in the brain. Additionally, NaB acts as an inhibitor of the cell-surface receptor CD11b, reducing the physical activation state of microglia and preserving neighboring neurons from bystander excitotoxicity.
- Inhibition of Tau Hyperphosphorylation and Aβ Aggregation: The neuropathological hallmarks of Alzheimer's disease include extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. The B-type procyanidin oligomers and trans-cinnamaldehyde isolated from *Cinnamomum zeylanicum* interact directly with these proteins. Cinnamaldehyde binds to the two cysteine residues (Cys291 and Cys322) of the microtubule-binding domain of tau, preventing the conformational shift required for filament formation and subsequent tangle assembly. Concurrently, the procyanidin oligomers interfere with the hydrophobic interactions that drive the self-assembly of monomeric Aβ into toxic oligomeric configurations, thereby facilitating non-toxic off-pathway aggregation and protecting synaptic terminals from oligomer-induced synaptic dysfunction.

3.4.3. Preclinical and Clinical Evidence

The multi-target efficacy of *Cinnamomum zeylanicum* is validated by extensive preclinical data. *In vitro* studies show that both bark extracts and purified trans-cinnamaldehyde exert powerful antioxidant effects [65]. These extracts show strong radical scavenging activity in DPPH and ABTS assays, suppress lipid peroxidation in brain homogenates, and protect differentiated PC12 cells from glutamate-induced excitotoxicity by maintaining intracellular glutathione levels and preventing mitochondrial depolarization. *In vitro* co-incubation assays also confirm that cinnamon-derived procyanidins inhibit the enzymatic activity of beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), the rate-limiting enzyme in Aβ production, while simultaneously destabilizing pre-formed Aβ fibrils in a dose-dependent manner [68,69].

These cellular mechanisms translate directly to *in vivo* models of neurological disorders. In rodent models of diabetes mellitus, chronic oral administration of *Cinnamomum zeylanicum* extracts reduces systemic hyperglycemia while concurrently lowering oxidative stress markers, such as malondialdehyde (MDA), within the cerebral cortex and hippocampus [71]. In rat models of formaldehyde-induced neurotoxicity, daily treatment with a standardized methanolic cinnamon extract significantly improved spatial memory performance in the Morris water maze. This cognitive improvement was accompanied by a marked reduction in the expression of phosphorylated tau at the Thr231 epitope, a decrease in active caspase-3 and caspase-9 levels, and the preservation of neuronal morphology within the CA1 region of the hippocampus [73].

Oral administration of a formulation containing cinnamon extract resulted in histopathological neuroprotection in a Sprague-Dawley rat model of traumatic brain injury (TBI). The treated group showed a significant reduction in cerebral edema, decreased glial fibrillary acidic protein (GFAP) reactivity, and a lower rate of post-traumatic apoptotic neuronal death within the perilesional cortex [74]. These findings show the therapeutic potential of the plant's active constituents in protecting the central nervous system against both chronic neurodegenerative processes and acute traumatic injuries.

3.5. *Rhodiola rosea*

Rhodiola rosea, also known as Golden Root, Roseroot, or Arctic Root, is a high-altitude herbaceous perennial belonging to the Crassulaceae family [77]. Naturally occurring in the cold mountain crevices of Siberia, Northern Europe, and North America, this plant has been used for centuries in traditional Scandinavian, Russian, and Chinese medicine systems to counteract the physiological consequences of physical fatigue, high-altitude hypoxia, and psychological stress [78]. Recognized in contemporary pharmacology as a classic adaptogen, *Rhodiola rosea* increases non-specific cellular resistance to environmental stressors, stabilizes systemic homeostasis, and supports cognitive reserve during prolonged periods of mental fatigue and neurological strain [79,80].

Figure 5. Flowers and Leaves of *Rhodiola rosea*

3.5.1. Phytochemical Profile and Structural Chemistry

The adaptogenic and neuroprotective properties of *Rhodiola rosea* reside primarily within its thick rhizomes and roots. Phytochemical analyses have identified approximately twenty-eight bioactive compounds, which are classified into six distinct chemical groups: phenylpropanoids, phenylethanol derivatives, flavonoids, monoterpenes, triterpenes, and phenolic acids [81]. The major chemical markers used for standardization are the phenylpropanoids, collectively referred to as rosavins, which include rosavin ($C_{20}H_{28}O_{10}$), rosin ($C_{15}H_{20}O_6$), and rosarin ($C_{20}H_{28}O_{10}$).

The phenylethanol derivatives are represented by salidroside ($C_{14}H_{20}O_7$), also known as rhodioloside, and its aglycone precursor p-tyrosol ($C_8H_{10}O_2$) [81,82]. The flavonoid fraction consists of rodiolin, rodionin, rodiosin, and tricin, which possess direct antioxidant and cytoprotective properties. The monoterpene group includes rosiridol and rosaridin, while the triterpene profile is dominated by β-sitosterol and daucosterol. Phenolic acids, such as gallic acid, caffeic acid, and chlorogenic acid, contribute further to the extract's robust free radical scavenging capacity. The synergistic interaction between the rosavin complex and salidroside is essential; while salidroside is found in other *Rhodiola* species, the presence of the rosavin trio is a unique chemical signature of authentic *Rhodiola rosea* [81].

3.5.2. Molecular and Cellular Mechanisms of Action

The neuropharmacological actions of *Rhodiola rosea* operate through several distinct molecular pathways:

- HPA Axis Regulation and Neuropeptide Y (NPY) Stimulation: As a classic adaptogen, *Rhodiola rosea* directly modulates the mammalian stress response. Under chronic stress, the extract prevents the hyperactivation of the HPA axis, stabilizing circulating cortisol levels and reducing the depletion of vital neuropeptides. Specifically, the active component salidroside stimulates the expression and release of neuropeptide Y (NPY) in glial cells. The upregulation of NPY suppresses the firing of stress-induced neurons in the amygdala and hypothalamus, maintaining physiological homeostasis and mitigating stress-induced cognitive impairment.
- Inhibition of Monoamine Oxidases (MAO-A and MAO-B): *Rhodiola rosea* extracts act as moderate, non-selective inhibitors of the mitochondrial enzymes monoamine oxidase A and B (MAO-A and MAO-B). These enzymes are responsible for the oxidative deamination of biogenic amines. By inhibiting their enzymatic activity, the plant's active constituents prevent the degradation of essential neurotransmitters, including serotonin (5-HT), dopamine, and norepinephrine, within the synaptic cleft. This inhibition increases the local concentrations and prolongs the biological activity of these monoamines, contributing to the antidepressant, anxiolytic, and attention-enhancing effects observed clinically.
- Hormetic Activation of Cellular Resilience Pathways: The cellular survival benefits of salidroside often follow a biphasic or hormetic dose-response relationship. At moderate therapeutic concentrations, salidroside induces mild, non-lethal cellular stress that activates endogenous adaptive survival pathways. This activation includes the upregulation of heat shock protein 70 (Hsp70), the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant pathway, and erythropoietin (EPO) expression. The coordination of these pathways enhances mitochondrial respiratory capacity, increases the transcription of endogenous antioxidant enzymes, and renders neurons highly resilient to subsequent lethal oxidative or ischemic injuries.

Table 2. Molecular and Cellular Neuroprotective Mechanisms of Selected Phytopharmaceuticals

Plant Species	Bioactive Agent(s)	Molecular Targets & Pathways	Downstream Cellular and Physiological Effects
Withania somnifera	Withanolide A, Sominone, Withanamides A & C	Glucocorticoid receptors, low-density lipoprotein receptor-related protein (LRP), Aβ hydrophobic core	Alleviates chronic HPA axis hyperactivity, lowers circulating cortisol, accelerates clearance of amyloid-beta across the blood-brain barrier, promotes neurite outgrowth and axonal reconstruction
Bacopa monnieri	Bacoside A complex, Bacopaside I	Acetylcholinesterase (AChE), TrkB receptor, NF-κB signaling cascade	Inhibits acetylcholine degradation in synaptic clefts, upregulates hippocampal BDNF expression to stimulate dendritic arborization, suppresses microglial secretion of pro-inflammatory cytokines (TNF-α, IL-1β)
Valeriana officinalis	Valerenic acid, Linarin, Valepotriates	Postsynaptic GABAA receptors (β2/β3 subunits), GABA transaminase (GABA-T), GAT transporter	Increases chloride ion (Cl^-) influx causing post-synaptic hyperpolarization, reduces catabolic breakdown of synaptic GABA, restricts presynaptic reuptake to prolong inhibitory transmission
Cinnamomum zeylanicum	Trans-cinnamaldehyde, B-type procyanidins	Tau microtubule-binding domain (Cys291 and Cys322), cAMP/CREB pathway, NF-κB	Blocks conformational shifting of tau to prevent neurofibrillary tangle formation, metabolizes to sodium benzoate (NaB) to upregulate hippocampal BDNF and NT-3, inhibits microglial activation
Rhodiola rosea	Salidroside, Rosavin, p-Tyrosol	HPA axis, Neuropeptide Y (NPY), Monoamine Oxidases (MAO-A/MAO-B), Nrf2 pathway	Suppresses excessive sympathetic firing under chronic stress, halts enzymatic degradation of biogenic amines (serotonin, dopamine, norepinephrine), activates adaptive cytoprotective heat shock protein 70 (Hsp70)

3.5.3. Preclinical and Clinical Evidence

The neuroprotective efficacy of *Rhodiola rosea* is strongly supported by preclinical research. *In vitro* studies using PC12 and N2A neuroblastoma cell lines show that pre-treatment with standardized ethanolic extracts or isolated salidroside significantly reduces intracellular reactive oxygen species (ROS) accumulation and prevents apoptotic cell death induced by hydrogen peroxide, glutamate excitotoxicity, and methylglyoxal (MG) toxicity [86,87]. In lipopolysaccharide (LPS)-stimulated BV2 microglial cell models, the active compounds suppress the phosphorylation of mitogen-activated protein kinases (MAPK), specifically pJNK and p-p38, leading to a significant reduction in the release of pro-inflammatory cytokines and nitric oxide [88].



Figure 6. Neuro-cellular targets of the five selected phytomedicines.

In vivo studies confirm these neuroprotective and neurorescue properties. In a rodent model of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), daily oral administration of *Rhodiola rosea* extract (250 mg/kg for twenty-one days) rescued dopaminergic neurons in the substantia nigra pars compacta, restored striatal dopamine concentrations, and significantly recovered motor coordination deficits [90]. In an Alzheimer's disease model induced by the intracerebroventricular injection of streptozotocin (ICV-STZ), treatment with the extract protected against hippocampal CA1 neuronal injury, decreased lipid peroxidation, and improved spatial learning and memory performance in the Morris water maze [91]. In acute stroke models involving middle cerebral artery occlusion (MCAO), treatment with salidroside significantly reduced total infarct volume, decreased brain swelling, and restored motor function by protecting the integrity of the blood-brain barrier [92, 93].



Figure 7. Intracellular Signaling Pathways and Synaptic Plasticity

Table 3. Preclinical (*In Vivo*) Evidence in Central Nervous System Disease Models

Plant Species	Experimental Animal Model	Dosage, Route, & Treatment Duration	Neurological & Histopathological Outcomes	References
Withania somnifera root extract	H_2O_2 and Aβ1-42 neurotoxicity in differentiated PC12 cells	Variable concentrations in vitro	Restored cell viability, prevented mitochondrial depolarization, suppressed caspase-3 expression, preserved cell morphology	[27]
Bacopa monnieri standardized extract	MPTP-induced mouse model of Parkinson's disease	40 mg/kg orally for up to 3 weeks	Rescued dopaminergic neurons in substantia nigra pars compacta, lowered microglial iNOS and astrocyte GFAP activation, reduced lipid peroxidation	[44]
Valeriana officinalis hydroalcoholic extract	Ovalbumin-sensitized rat model of neuroimmune stress	200 mg/kg orally for 21 days	Ameliorated depressive-like behaviors in forced swim tests, decreased central and systemic inflammatory cytokines	[57]
Cinnamomum zeylanicum methanolic extract	Formaldehyde-induced neurotoxicity in Wistar rats	100 mg/kg or 200 mg/kg orally for 30 days	Improved spatial memory performance in Morris water maze, decreased hyperphosphorylated tau at Thr231, suppressed hippocampal apoptosis	[73]
Rhodiola rosea standardized extract	ICV-STZ-induced rat model of Alzheimer's disease	50 mg/kg to 250 mg/kg orally for 21 days	Rescued hippocampal CA1 neurons from degeneration, decreased lipid peroxidation, normalized spatial learning deficits	[91]



Figure 8. Pharmacokinetics and metabolic kinetics governing blood-brain barrier transport of phytopharmaceuticals

Table 4. Evaluation of Human Clinical Trials for Neurological and Cognitive Outcomes

Plant Species / Standardized Preparation	Study Design & Patient Population	Dosage & Treatment Duration	Principal Clinical Findings	Safety, Tolerability, & Adverse Event Profiles	References
Bacopa monnieri (standardized extract)	Randomized, double-blind, placebo-controlled trial in elderly cohorts	300 mg orally once daily for 12 weeks	Significantly enhanced verbal learning, cognitive processing speed, and delayed word recall; decreased subjective state anxiety	Well tolerated; rare reports of transient gastrointestinal motility issues and mild abdominal discomfort	[34]
Valeriana officinalis (aqueous-alcoholic dry extract)	Randomized, double-blind, placebo-controlled trial in patients with sleep complaints	450 mg or 900 mg orally at bedtime for 4 weeks	Improved subjective sleep quality, shortened sleep latency, and enhanced deep, slow-wave sleep architecture	Favorable safety profile; devoid of next-day cognitive impairment, muscle relaxation, or hangover effects	[47]
Rhodiola rosea (standardized dry extract)	Randomized, double-blind, placebo-controlled trials in individuals with life-stress symptoms	200 mg orally twice daily for 4 weeks	Decreased objective burnout indices, minimized mental fatigue during complex cognitive tasks, increased attention span	Highly favorable therapeutic index; mild, transient cases of dizziness and dry mouth; zero dependency or withdrawal signs	[80,94]

Table 5. Adverse Clinical Events and Safety

Botanical Lead	Documented Severe Adverse Event	Postulated Biochemical / Pathological Mechanism	Clinical Presentation & Monitoring Parameters	Resolution Status & Reversibility	References
Withania somnifera	Drug-induced acute liver injury	Cholestatic hepatitis secondary to direct herbal metabolite cytotoxicity or idiosyncratic immune response	Jaundice, pruritus, dark urine, marked elevations in serum bilirubin and alkaline phosphatase	Fully reversible within 1 to 5 months following complete cessation of the botanical supplement	[25]
Withania somnifera	Thyrotoxicosis	Direct stimulation of the thyroid follicular cells, upregulating T3 and T4 hormone synthesis	Tremor, palpitations, weight loss, heat intolerance, supraventricular tachycardia	Fully reversible; requires monitoring of free thyroid-stimulating hormone (TSH), free T4, and free T3	[26]
Valeriana officinalis	Mild hepatotoxicity (rare)	Synergistic idiosyncratic cellular strain associated with high-dose ingestion of valepotriate components	Elevated serum alanine transaminase (ALT) and aspartate transaminase (AST); standard liver function tests	Reversible; typically resolves completely within weeks upon withdrawal of the preparation	[52,58]
Cinnamomum cassia / *zeylanicum* adulteration	Coumarin-induced hepatotoxicity	Metabolic oxidation of high concentrations of coumarin leading to reactive epoxide intermediates in hepatocytes	Elevation of transaminases; requires verification of the species profile to confirm authentic *C. zeylanicum* (naturally low coumarin)	Reversible; highly dependent on utilizing authentic, non-adulterated Ceylon cinnamon	[61]

These findings translate consistently into human clinical trials. Randomized, double-blind, placebo-controlled studies show that standardized *Rhodiola rosea* preparations significantly reduce symptoms of burnout, decrease subjective mental fatigue during prolonged cognitive tasks, and improve overall attention span, working memory capacity, and reaction time in individuals experiencing chronic stress [94,95]. The extract exhibits a highly favorable safety profile, with a low incidence of mild, transient

adverse effects and no documented risk of physical dependency or severe withdrawal symptoms, supporting its clinical utility as a natural adaptogen for managing stress-induced cognitive decline.

4. Conclusion

The systematic validation of traditional ethnopharmacological leads represents a promising pathway for modern neurotherapeutic drug discovery. *Withania somnifera*, *Bacopa monnieri*, *Valeriana officinalis*, *Cinnamomum zeylanicum*, and *Rhodiola rosea*, these traditional remedies contain complex chemical structures that target multiple pathological pathways simultaneously. Rather than operating via the single-target mechanisms characteristic of synthetic pharmaceuticals, these botanical leads achieve clinical efficacy through synergistic interactions. They modulate primary neurotransmitter systems, suppress neuroinflammatory cascades, mitigate chronic oxidative stress, and directly prevent the toxic aggregation of amyloid-beta, hyperphosphorylated tau, and alpha-synuclein. To successfully utilize these phytopharmaceuticals in contemporary clinical neurology, several scientific challenges must be addressed. More research should prioritize standardizing extraction methodologies to maintain consistent ratios of active secondary metabolites across commercial preparations. Rigorous pharmacokinetic profiling is required to optimize the blood-brain barrier permeability of these complex mixtures and determine their potential for drug-drug interactions with conventional neuropathic medications. Bridging the gap between empirical historical use and contemporary evidence-based medicine through reverse pharmacology paradigms will support the development of safe, effective, and multi-target neurotherapeutics for progressive central nervous system disorders.

References

[1] Kulamarva K, Shivakumar V, Chikkanna U, Ramakrishna K, Bhargav H, Varambally S. Role of Ayurveda in the management of psychotic disorders: A systematic review of clinical evidence. J Ayurveda Integr Med. 2023;14(3):100720.

[2] Jain SB, Chawardol SG. Therapeutic Role of Herbal Drugs in the Management of Mental Disorders: An Ayurveda Review. J Drug Deliv Ther. 2019;9(4-A):877-879.

[3] Uddin MJ, Zidorn C. Traditional herbal medicines against CNS disorders from Bangladesh. Nat Prod Bioprospect. 2020;10(6):377–410.

[4] Rauf A, Rahman MM. Potential therapeutics against neurological disorders: Natural products-based drugs. Front Pharmacol. 2022;13:950457.

[5] Lin CH, Hsieh CL. Chinese Herbal Medicine for Treating Epilepsy. Front Neurosci. 2021;15:682821.

[6] Pattanaik S, Sharma D. Review on Ayurvedic plant based compounds to cure the neurological disorders. Int J Pharmacogn Life Sci. 2023;4(1):1-12.

[7] Yao R, Heinrich M, Zhang B, Wei X, Qi Y, Gao W. Single botanical drugs in the Ayurvedic Pharmacopoeia of India — a quantitative ethnobotanical analysis. Front Pharmacol. 2023;14:1136446.

[8] Vaidya ADB, Devasagayam TPA. Current status of herbal drugs in India: An overview. J Clin Biochem Nutr. 2007;41(1):1-11.

[9] Balachandran P, Govindarajan R. Ayurvedic drug discovery. Expert Opin Drug Discov. 2007;2(12):1631-1652.

[10] Vaidya ADB. Reverse pharmacological correlates of Ayurvedic drug actions. Indian J Pharmacol. 2006;38(5):311–315.

[11] Halder S, Anand U, Nandy S, Oleksak P, Qusti SA, Alshammari EM, et al. Herbal drugs and natural bioactive products as potential therapeutics: A review on pro-cognitives and brain boosters perspectives. Saudi Pharm J. 2021;29(8):879-907.

[12] Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, et al. Historical perspective of traditional indigenous medical practices. Evid Based Complement Alternat Med. 2014;2014:525340.

[13] Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.

[14] Sen S, Chakraborty R. Revival, modernization and integration of Indian traditional herbal medicine in clinical practice: Importance, challenges and future. J Tradit Complement Med. 2016;7(2):234–244.

[15] Rizvi SAA, Kashyap D, Raj S, et al. Introduction to Traditional Medicine and Their Role in Sustainable Healthcare Delivery. J Tradit Complement Med. 2022;12(4):331–339.

[16] Ruhela RK, Soni S, Medhi B. Therapeutic Potential of *Withania Somnifera* in CNS Disorders: A Neuropharmacological Review. Eur J Med Plants. 2016;16(2):1-12.

[17] Prajapati PK, Gupta GP, Chahar DS, Singhal HK, Sharma B, et al. Exploring the Therapeutic Potential of Ashwagandha *(Withania somnifera)* in Alleviating Stress and Anxiety. J Pharm Res Int. 2025;37(4):116-126.

[18] Bano A, Sharma N, Dhaliwal HS, Sharma V. A systematic and comprehensive review on *Withania somnifera* (L.) Dunal – An Indian Ginseng. J Pharm Res Int. 2015;7(2):63-75.

[19] Bashir A, Nabi M, Tabassum N, Afzal S, Ayoub M. An updated review on phytochemistry and molecular targets of *Withania somnifera* (L.) Dunal (Ashwagandha). Front Pharmacol. 2023;14:1049334.

[20] Kuboyama T, Tohda C, Komatsu K. Effects of Ashwagandha (Roots of *Withania somnifera*) on Neurodegenerative Diseases. Biol Pharm Bull. 2014;37(6):892–897.

[21] Chaudhari KS, Tiwari RR, Chaudhari SS, Joshi SV, Singh HB. *Withania somnifera* as an Adjunctive Treatment for Refractory Restless Legs Syndrome in Parkinson's Disease: A Case Report. Cureus. 2021;13(12):e20775.

[22] Gupta A, Singh P, Singh D. Steroidal lactones from *Withania somnifera*, an ancient plant for novel medicine. Molecules. 2009;14(7):2373-2393.

[23] Matsuda H, Morikawa T, Hasada K, et al. Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of *Withania somnifera* Dunal. Chem Pharm Bull. 2001;49(6):778-780.

[24] Parihar S. A literature review on pharmacological activities of Withania somnifera. Biological Sciences. 2022;2(1):147-154.

[25] Tóth M, Benedek AE, Longerich T, Seitz HK. Ashwagandha induced acute liver injury: a case report. Clin Case Rep. 2023;11(3):e7078.

[26] Kamal HI, Patel K, Brdak A, Heffernan J, Ahmad N. Ashwagandha as a Unique Cause of Thyrotoxicosis Presenting With Supraventricular Tachycardia. Cureus. 2022;14(3):e23494.

[27] Kumar S, Seal CJ, Howes MJR, Kite GC, Okello EJ. *In vitro* protective effects of *Withania somnifera* (L.) Dunal root extract against hydrogen peroxide and β-amyloid (1–42)-induced cytotoxicity in differentiated PC12 cells. Phytother Res. 2010;24(10):1567-1574.

[28] Balkrishna A, Nain P, Chauhan A, Sharma N, Gupta A, Ranjan R, Varshney A. Super Critical Fluid Extracted Fatty Acids from *Withania somnifera* Seeds Repair Psoriasis-Like Skin Lesions and Attenuate Pro-Inflammatory Cytokines (TNF-α and IL-6) Release. Biomolecules. 2020;10(2):185.

[29] Li YX, Zhang ZF, Wu YM, Shi L, Shen HX, Seeram NP, Ma H, Lu YM. Structural characterization and immunostimulatory effects of polysaccharide AP-1 from ashwagandha (*Withania somnifera*) roots. Int J Biol Macromol. 2025;311(Pt 4):143855.

[30] Patel SB, Rao NJ, Hingorani LL. Safety assessment of *Withania somnifera* extract standardized for Withaferin A: acute and subacute toxicity study. J Ayurveda Integr Med. 2016;7(1):30–37.

[31] Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb *Bacopa monnieri*. Rejuvenation Res. 2013;16(4):313-326.

[32] Raghav S, Singh H, Dalal PK, Srivastava JS, Asthana OP. Randomized controlled trial of standardized *Bacopa monniera* extract in age-associated memory impairment. Indian J Psychiatry. 2006;48(4):238-242.

[33] Mathew J, Balakrishnan S, Antony S, Abraham PM, Paulose CA. Decreased GABA receptor in the cerebral cortex of epileptic rats: effect of *Bacopa monnieri* and Bacoside-A. J Biomed Sci. 2012;19:25.

[34] Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized *Bacopa monnieri* extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707-713.

[35] Sivasangari K, Rajan KE. Standardized *Bacopa monnieri* extract ameliorates learning and memory impairments through synaptic protein, neurogranin, pro- and mature BDNF signalling, and HPA axis in prenatally stressed rat offspring. Antioxidants. 2020;9(12):1229.

[36] Dethe S, Deepak M, Agarwal A. Elucidation of molecular mechanism(s) of cognition enhancing activity of BacoMind®, a standardized extract of *Bacopa monnieri*. Pharmacogn Mag. 2016;12(47 Suppl):S482-S487.

[37] Thomas RB, Joy S, Ajayan MS, Paulose CS. Neuroprotective potential of *Bacopa monnieri* and Bacoside A against dopamine receptor dysfunction in the cerebral cortex of neonatal hypoglycaemic rats. Cell Mol Neurobiol. 2013;33(8):1065-1074.

[38] Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive enhancing effects of *Bacopa monnieri*: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647-652.

[39] Wattanathorn J, Mator L, Muchimapura S, et al. Positive modulation of cognition and mood in healthy elderly volunteer following the administration of Centella asiatica. J Ethnopharmacol. 2008;116(2):325-332.

[40] Gościniak A, Stasiłowicz-Krzemień A, Szeląg M, Pawlak J, Skiera I, Kwiatkowska H, et al. *Bacopa monnieri*: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability. Nutrients. 2025;17(11):1939.

[41] Sekhar VC, Viswanathan G, Baby S. Insights into the molecular aspects of neuroprotective Bacoside A and Bacopaside I. Curr Neuropharmacol. 2019;17(5):438–446.

[42] Leung HW, Foo G, Banumurthy G, Chai X, Ghosh S, Mitra-Ganguli T, et al. The effect of *Bacopa monnieri* on gene expression levels in SH-SY5Y human neuroblastoma cells. PLoS One. 2017;12(8):e0182984.

[43] Mathur D, Goyal K, Koul V, Anand A. The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (Bacopa monniera). Front Pharmacol. 2016;7:44.

[44] Singh B, Pandey S, Rumman M, Kumar S, Kushwaha PP, Verma R, et al. Neuroprotective and Neurorescue Mode of Action of *Bacopa monnieri* (L.) Wettst in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson's Disease: An In Silico and *In Vivo* Study. Front Pharmacol. 2021;12:616413.

[45] Fatima U, Roy S, Ahmad S, Ali S, Elkady WM, Khan I, et al. Pharmacological attributes of *Bacopa monnieri* extract: Current updates and clinical manifestation. Front Nutr. 2022;9:972379.

[46] Li J, Li X, Wang C, Zhang M, Ye M, Wang Q. The potential of Valeriana as a traditional Chinese medicine: traditional clinical applications, bioactivities, and phytochemistry. Front Pharmacol. 2022;13:973138.

[47] Shekhar HC, Joshua L, Thomas JV. Standardized extract of *Valeriana officinalis* improves overall sleep quality in human subjects with sleep complaints: a randomized, double-blind, placebo-controlled, clinical study. Adv Ther. 2024;41(1):246-261.

[48] Shinjyo N, Waddell G, Green J. Valerian Root in Treating Sleep Problems and Associated Disorders—A Systematic Review and Meta-Analysis. J Evid Based Integr Med. 2020;25:2515690X20967323.

[49] Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119(12):1005-1012.

[50] Huang T, et al. Management of insomnia: a place for traditional herbal remedies. Sleep Med Rev. 2005;9(1):47-56.

[51] Fernández S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from *Valeriana officinalis*. Pharmacol Biochem Behav. 2004;77(2):399-404.

[52] Kırmızıbekmez H, Erdoğan M, Yanıkkaya Demirel G. The genus Valeriana L.: ethnopharmacology, phytochemistry and biological activities—an updated review. Phytochem Rev. 2025; [ahead of print].

[53] Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med. 2007;73(15):1298-1304.

[54] Cavadas C, Araújo I, Cotrim MD, Amaral T, Cunha AP, Macedo T, et al. *In vitro* study on the interaction of *Valeriana officinalis* L. extracts and their amino acids on GABA(A) receptor in rat brain. Arzneimittelforschung. 1995;45(7):753–755.

[55] Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH. *Valeriana officinalis* root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine. 2010;17(8-9):674–678.

[56] Becker A, Felgentreff F, Schröder H, Meier B, Brattström A. The anxiolytic effects of a Valerian extract is based on Valerenic acid. BMC Complement Altern Med. 2014;14:267.

[57] Neamati A, Chaman F, Hosseini M, Boskabady MH. The effects of *Valeriana officinalis* L. hydroalcoholic extract on depression like behavior in ovalbumin sensitized rats. J Pharm Bioallied Sci. 2014;6(2):97–103.

[58] Pilerood SA, Prakash J. Nutritional and medicinal properties of valerian (*Valeriana officinalis*) herb: A review. Int J Food Sci Nutr Diet. 2013;1(1):25–33.

[59] Kumar S, Kumari R. Cinnamomum: review article of essential oil compounds, ethnobotany, antifungal and antibacterial effects. Open Access J Sci. 2019;3(1):13-16.

[60] Kumar S, Kumari R, Mishra S. Pharmacological properties and their medicinal uses of Cinnamomum: a review. J Pharm Pharmacol. 2019;71(12):1735-1761.

[61] Guo J, Jiang X, Tian Y, Yan S, Liu J, Xie J, et al. Therapeutic Potential of Cinnamon Oil: Chemical Composition, Pharmacological Actions, and Applications. Pharmaceuticals (Basel). 2024;17(12):1700.

[62] Sabri H, Deravi N. Therapeutic potential of cinnamon for neurological disorders: a mini-review. Neurology Asia. 2022;27(1):1-17.

[63] Fu Y, Yang P, Zhao Y, Zhang L, Zhang Z, Dong X, et al. Trans-cinnamaldehyde inhibits microglial activation and improves neuronal survival against neuroinflammation in BV2 microglial cells with lipopolysaccharide stimulation. Evid Based Complement Alternat Med. 2017;2017:4730878.

[64] Xu Q, Chen Z, Zhu B, Li Y, Reddy MB, Liu H, et al. Neuroprotective Effects of B-Type Cinnamon Procyanidin Oligomers on MPP^+-Induced Apoptosis in a Cell Culture Model of Parkinson's Disease. Molecules. 2021;26(21):6422.

[65] Wanakhachornkrai O, Banglao W, Thongmee A, Sukplang P. Determination of antioxidant, anti-aging and cytotoxicity activity of the essential oils from *Cinnamomum zeylanicum*. J Microbiol Biotechnol Food Sci. 2020;10(3):436–440.

[66] Utchariyakiat I, Surassmo S, Jaturanpinyo M, Khuntayaporn P, Chomnawang MT. Efficacy of cinnamon bark oil and cinnamaldehyde on anti-multidrug resistant Pseudomonas aeruginosa and the synergistic effects in combination with other antimicrobial agents. BMC Complement Altern Med. 2016;16:158.

[67] Nazareno AM, Purnamasari L, dela Cruz JF. *In vivo* and *in vitro* anti-diabetic effects of cinnamon (Cinnamomum sp.) plant extract: A review. Canrea J Food Technol Nutr Culin. 2022;5(2):151–171.

[68] Momtaz S, Hassani S, Khan F, Ziaee M, Abdollahi M. Cinnamon, a promising prospect towards Alzheimer's disease. Pharmacol Res. 2018;130:241-258.

[69] Shodiq MJ, Hartono F, Khaerunnisa S, Machin A. Analysis of Potential *Cinnamomum zeylanicum* Blume Essential Oil Against Alzheimer's Disease: A Molecular Docking Study. J Pharm Pharm Sci / Jurnal Farmasi dan Ilmu Kefarmasian Indonesia. 2023;10(1):111-125.

[70] Hatte S, Mandave P, Jadhav A. Evaluation of anticancer activity of *Cinnamomum zeylanicum* against blood cancer cell line. J Microbiol Biotechnol Food Sci. 2025;14(4):e11729.

[71] Cordero Pérez P, Hernández Cruz FE, Garza Guzmán D, Moreno Peña DP, Sánchez Martínez C, Torres González L, et al. Antidiabetic and Anti-Inflammatory Effect of Cinnamomum cassia Oil in Alloxan Induced Diabetic Rats. Pharmaceuticals (Basel). 2024;17(9):1135.

[72] Davoudi F, Ramazani E. Antioxidant and anti-inflammatory effects of Cinnamomum species and their bioactive compounds: An updated review of the molecular mechanisms. Physiol Pharmacol. 2024;28(2):99–116.

[73] Sayad Fathi S, Zaminy A, Babaei P, Yousefbeyk F, Azizi N, Nasiri E. The methanolic extract of *Cinnamomum zeylanicum* bark improves formaldehyde-induced neurotoxicity through reduction of phospho-tau (Thr231), inflammation, and apoptosis. EXCLI J. 2020;19:671–686.

[74] Rosyidi RM, Wardhana DP, Priyanto B, Januarman J, Zulkarnaen DA, et al. The effect of Centella asiatica, cinnamon, and spirulina as neuroprotective based on histopathological findings in rats Sprague Dawley with traumatic brain injury. Surg Neurol Int. 2024;15:217–225.

[75] Sandamali JAN, Hewawasam RP, Jayatilaka KAPW, Mudduwa LKB. *Cinnamomum zeylanicum* Blume (Ceylon cinnamon) bark extract attenuates doxorubicin-induced cardiotoxicity in Wistar rats. Saudi Pharm J. 2021;29(8):820–832.

[76] Sharafeldin K, Rizvi MR. Effect of traditional plant medicines (*Cinnamomum zeylanicum* and Syzygium cumini) on oxidative stress and insulin resistance in streptozotocin-induced diabetic rats. J Basic Appl Zool. 2015;72:126–134.

[77] Panossian A, Wikman G, Sarris J. Rosenroot (*Rhodiola rosea* L.): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010;17(7):481-493.

[78] Chiang HM, Chen HC, Wu CS, Wu PY, Wen KC. Rhodiola plants: chemistry and biological activity. J Food Drug Anal. 2015;23(3):359-369.

[79] Ishaque S, Shamseer L, Bukutu C, Vohra S. *Rhodiola rosea* for physical and mental fatigue: a systematic review. BMC Complement Altern Med. 2012;12:70.

[80] Stojcheva EI, Quintela JC. The effects of *Rhodiola rosea* L. preparations in alleviating various aspects of life-stress symptoms and stress-induced conditions—encouraging clinical evidence. Molecules. 2022;27(12):3902.

[81] Saunders D, Poppleton D, Struchkov A, Ireland R. Analysis of five bioactive compounds from naturally occurring *Rhodiola rosea* in eastern Canada. Can J Plant Sci. 2014;94(4):741-748.

[82] Grech-Baran M, Sykłowska-Baranek K, Pietrosiuk A. Biotechnological approaches to enhance salidroside, rosin and its derivatives production in selected Rhodiola spp. in vitro cultures. Phytochem Rev. 2015;14(4):657-674.

[83] Zhang W, Huai Y, Miao Z, Chen C, Shahen M, Rahman SU, et al. Systems pharmacology approach to investigate the molecular mechanisms of herb *Rhodiola rosea* L. radix. Drug Dev Ind Pharm. 2018;44(3):456-464.

[84] van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K. Monoamine oxidase inhibition by *Rhodiola rosea* L. roots. J Ethnopharmacol. 2009;122(2):397–401.

[85] Ma GP, Zheng Q, Xu MB, Zhou XL, Lu L, Li ZX, et al. *Rhodiola rosea* L. improves learning and memory function: preclinical evidence and possible mechanisms. Front Pharmacol. 2018;9:1415.

[86] Kim KJ, Jung YS, You DM, Lee SH, Lee G, Kwon KB, et al. Neuroprotective effects of ethanolic extract from dry *Rhodiola rosea* L. rhizomes. Food Sci Biotechnol. 2021;30(2):287–297.

[87] Wang CH, Safwan S, Cheng MC, Liao TY, Cheng LC, Chen TA, et al. Protective evaluation of compounds extracted from root of *Rhodiola rosea* L. against methylglyoxal induced toxicity in a neuronal cell line. Molecules. 2020;25(12):2801.

[88] Lee Y, Jung JC, Jang S, Kim J, Ali Z, Khan IA, et al. Anti-Inflammatory and Neuroprotective Effects of Constituents Isolated from *Rhodiola rosea*. Evid Based Complement Alternat Med. 2013;2013:514049.

[89] Calabrese EJ, Dhawan G, Kapoor R, Agathokleous E, Calabrese V. *Rhodiola rosea* and salidroside commonly induce hormesis, with particular focus on longevity and neuroprotection. Chem Biol Interact. 2023;380:110540.

[90] Jacob R, Nalini G, Chidambaranathan N. Neuroprotective effect of *Rhodiola rosea* Linn against MPTP induced cognitive impairment and oxidative stress. Ann Neurosci. 2013;20(2):47–51.

[91] Qu ZQ, Zhou Y, Zeng YS, Li Y, Chung P. Pretreatment with *Rhodiola rosea* extract reduces cognitive impairment induced by intracerebroventricular streptozotocin in rats: implication of anti-oxidative and neuroprotective effects. Biomed Environ Sci. 2009;22(4):318–326.

[92] Zhong ZF, Han J, Zhang JZ, Xiao Q, Chen JY, Zhang K, et al. Neuroprotective effects of salidroside on cerebral ischemia/reperfusion-induced behavioral impairment involves the dopaminergic system. Front Pharmacol. 2019;10:1433.

[93] Drafi F, Bauerova K, Chrastina M, Taghdisiesfejír M, Rocha J, Direito R, et al. *Rhodiola rosea* L. extract, a known adaptogen, evaluated in experimental arthritis. Molecules. 2023;28(13):5053.

[94] Jówko E, Sadowski J, Długolęcka B, Gierczuk D, Opaszowski B, Cieśliński I. Effects of *Rhodiola rosea* supplementation on mental performance, physical capacity, and oxidative stress biomarkers in healthy men. J Sport Health Sci. 2018;7(4):473–480.

[95] Zhong Z, Han J, Zhang J, Xiao Q, Hu J, Chen L. Pharmacological activities, mechanisms of action, and safety of salidroside in the central nervous system. Drug Des Devel Ther. 2018;12:1479–1489.